Generic Name: histrelin

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: Endo Pharmaceuticals

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Vantas is a GnRH agonist approved for palliative treatment of advanced prostate cancer.

General Info

Testosterone and other male hormones (androgens) stimulate prostate cancer growth. Gonadotropin-releasing hormone (GnRH) agonists, also known as luteinizing hormone-releasing hormone (LHRH) agonists, block signals in the brain that direct the testicles to produce testosterone. Testosterone levels go up briefly (known as a flare) before falling to very low levels.


Dosing Info:

Vantas is a long-acting implant, inserted under the skin of the upper arm, that lasts for a year.

Side Effects

Common side effects include fatigue, hot flashes and mild reactions at the implant site. Medications that lower testosterone may lead to reduced sexual desire, erectile dysfunction and shrinkage of the testicles. Potential serious side effects include increased risk of diabetes and cardiovascular disease.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 19, 2018